Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEVKP in kidney transplantation
NCT03136848Completed
- Sponsor
- University Health Network
- Start
- Dec 2016
- Primary completion
- Jun 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of normothermic ex-vivo kidney perfusion solution - toronto in end stage renal disease (ESRD), sponsored by University Health Network. Primary endpoints: ratio of actual / eligible kidney grafts at 3 months and rate of kidney discard or graft failure attributable to the study intervention at 3 months. Started Dec 2016; status: completed.
02
Drugs
normothermic ex-vivo kidney perfusion solution - toronto
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03136848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136848.